Skip to main content

Table 8 The combined synergizing effects of Venetoclax on cellular apoptosis

From: BH3-mimetics: recent developments in cancer therapy

Cancer Cell Type Combined Apoptosis Ref
ALL LOUCY cell line doxorubicin, l-asparaginase, and dexamethasone [302]
AML Primary cells and U937 daunorubicin or cytarabine [303]
AML KOPT-K1 S63845 synergized [304]
AML MV4–11 and MOLM-13, KG-1a, U937, and THP-1 triptolide synergized [305]
AML Jurkat and Molt4 gemcitabine synergized [306]
AML Molm14 and OCI-AML3 VS-4718 [307]
AML/MDS/CMML Ex-vivo samples 5-azacytidine [112]
Breast 23 T Xenografts and MCF7 tamoxifen, AZD8055 [308]
CML KCL22 imatinib sensitized [309]
CRC Xenograft and RKO cell line LZT-106 synergized [310]
Diffuse BCL and FL Cell lines and TMD8 xenograft model ibrutinib synergized [311]
Leukemia, Lymphoma SU-DHL-4, OCI-Ly1 199R, SC-1199R and BCl and FL primary samples A-1592668 and analogue A-1467729 synergized [312]
Nasopharyngeal CNE-2, 5-8F S63845 synergized [293]
MM OPM2, H929 THZ1 synergized [313]
MM U266, KMS11, OPM2, RPMI8226 and KMS28-PE flavopiridol synergized [314]
Pancreatic MIA Paca-2 xenograft gemcitabine [301]
Soft Tissue Sarcoma Rhabdomyosarcoma, SW982 (synovial sarcoma) cells or primary cells bortezomib synergized [315]
  1. The cancer types are highlighted in bold (left column), non-synergy is highlighted by ‘-‘and the corresponding studies are referenced in the column on the right (Ref). Abbreviations: AML Acute Myelogenous Leukemia, ALL Acute Lymphoblastic Lymphoma, MDS Myelodysplastic syndrome, CMML Chronic myelomonocytic leukemia, BCL B-cell lymphoma, FL Follicular Lymphoma, MM Multiple myeloma